- Home
- BNTX vs WY Comparison
BNTX vs WY Comparison
Compare BNTX & WY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | WY |
|---|---|---|
| Founded | 2008 | 1900 |
| Country | Germany | United States |
| Employees | N/A | 9517 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5B | 17.4B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | BNTX | WY |
|---|---|---|
| Price | $90.59 | $23.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $140.12 | $29.00 |
| AVG Volume (30 Days) | 851.9K | ★ 5.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.47% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.45 |
| Revenue | N/A | ★ $6,905,000,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | $2.61 | $8.92 |
| P/E Ratio | ★ N/A | $53.80 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $79.81 | $21.16 |
| 52 Week High | $124.00 | $30.28 |
Technical Indicators
Market Signals| Indicator | BNTX | WY |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 24.95 |
| Support Level | N/A | $23.23 |
| Resistance Level | $112.30 | $24.03 |
| Average True Range (ATR) | 3.35 | 0.59 |
| MACD | -2.19 | -0.18 |
| Stochastic Oscillator | 32.92 | 0.20 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About WY Weyerhaeuser Company
Weyerhaeuser Co ranks among the world's key forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.